Panitch Howard B
Division of Pulmonary Medicine, Fifth Floor Wood Building, The Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104, USA.
Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S83-7; discussion S87-8. doi: 10.1097/01.inf.0000053890.66801.97.
Treatment of respiratory syncytial virus bronchiolitis rests primarily on supportive care with oxygen and fluid management. Other therapies commonly used include bronchodilators, corticosteroids and ribavirin, when considered appropriate. Small studies have also suggested that exogenous surfactant, helium/oxygen mixtures (heliox) and combination therapies may offer clinical benefit as well. Management of bronchiolitis can be facilitated by (1) recognizing the risks and benefits of various therapies, (2) understanding the markers of disease severity and (3) gaining familiarity with the time course of viral replication compared with presentation of symptoms. Although oxygen administration and judicious fluid replacement are the only interventions proved to be of reliable benefit to infants with bronchiolitis, newer studies support a role for adjunctive therapies aimed at relieving airway obstruction, especially when administered very early in the course of the illness or given to infants with more severe disease.
呼吸道合胞病毒细支气管炎的治疗主要基于支持性护理,包括氧气和液体管理。在认为合适的情况下,其他常用疗法包括支气管扩张剂、皮质类固醇和利巴韦林。小型研究还表明,外源性表面活性剂、氦/氧混合气(氦氧混合气)和联合疗法也可能带来临床益处。通过以下几点可以促进细支气管炎的管理:(1)认识各种疗法的风险和益处;(2)了解疾病严重程度的标志物;(3)熟悉病毒复制的时间进程与症状表现的比较。尽管给氧和合理补液是仅有的被证明对患细支气管炎的婴儿有可靠益处的干预措施,但新的研究支持辅助疗法在缓解气道阻塞方面的作用,特别是在疾病早期或给予病情较重的婴儿时使用。